23 , 24 However, the group of high-risk stage II patients showed a trend towards increased 5yDFSR (82.3% vs. 74.6%; HR: 0.72, 95% CI: 0.50–1.02) with FOLFOX, although again OS was not improved, possibly due to an excess of non-tumor-related deaths. 24 , 25 Stage II subgroup analyses for DFS and OS of the NSABP-C07 trial showed CIs including 1, with a HR favoring 5-FU/LV
1
—
—